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Graphical Abstract 
 
 
The periplasmic binding protein VctP of Vibrio cholerae, binds the Fe(III) complexes 
of a tetradentate salmochelin S1 mimic with higher affinity than does the periplasmic 
binding protein CeuE of Campylobacter jejuni. Both proteins select for ȁ-configured 
Fe(III) complexes and display a preference for bis(catecholates) over the 
tris(catecholate) siderophore enterobactin.  
 
Highlights 
x Synthesis of a mimic of the tetradentate stealth siderophore salmochelin S1 
x The periplasmic binding protein of Vibrio cholerae (VctP) binds the mimic strongly   
x VctP selects IRUȁ-configured Fe(III) complexes of the mimic 
x VctP displays a preference for bis(catecholate) over tris(catecholate) 
siderophores  
x The role of salmochelin in iron uptake by pathogens merits further investigation 
Abstract 
A mimic of the tetradentate stealth siderophore salmochelin S1, was synthesised, 
characterised and shown to form Fe(III) complexes with ligand-to-metal ratios of 1:1 
and 3:2. Circular dichroism spectroscopy confirmed that the periplasmic binding 
proteins CeuE and VctP of Campylobacter jejuni and Vibrio cholerae, respectively, 
bind the Fe(III) complex of the salmochelin mimic by preferentially selecting ȁ-
configured Fe(III) complexes. Intrinsic fluorescence quenching studies revealed that 
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VctP binds Fe(III) complexes of the mimic and structurally-related catecholate 
ligands, such as enterobactin, bis(2, 3-dihydroxybenzoyl-L-serine) and bis(2, 3-
dihydroxybenzoyl)-1, 5-pentanediamine with higher affinity than does CeuE. Both 
CeuE and VctP display a clear preference for the tetradentate bis(catecholates) over 
the tris(catecholate) siderophore enterobactin. These findings are consistent with 
reports that V. cholerae and C. jejuni utilise the enterobactin hydrolysis product bis(2, 
3-dihydroxybenzoyl)-O-seryl serine for the acquisition of Fe(III) and suggest that the 
role of salmochelin S1 in the iron uptake of enteric pathogens merits further 
investigation. 
Key words: Salmochelin, Stealth Siderophore Mimic, Iron Uptake, Vibrio cholerae, 
Periplasmic Binding Protein 
Introduction 
Iron is an essential element required for the survival and growth of bacteria within a 
host organism. Iron(II) is in scarce supply in aerobic environments, so iron(III) must 
be taken up, despite its poor aqueous solubility of 10-18-10-17 mol dm-3 at pH 7.1 
Requiring concentrations between 10-8 and 10-6 mol dm-3 for growth,2 complex 
strategies must be employed by bacteria for acquisition of sufficient iron for 
survival.1, 3 Siderophores are low molecular weight (<1500 Da) compounds with high 
affinity for iron(III) that are produced, secreted and employed by bacteria for iron(III) 
uptake. 2, 4 Vibrio cholerae acquires essential iron by producing the catecholate 
siderophore vibriobactin, and by poaching enterobactin and its linear hydrolysis 
products from competing bacteria in the surrounding environment ( 
 
Figure and scheme captions: 
Figure 1).5-8 
In response, some host organisms produce siderocalins which can bind a number of 
iron(III)-bound siderophores, including enterobactin and vibriobactin, with 
subnanomolar dissociation constants, and hinder bacterial iron(III)-siderophore 
uptake.9-15 However, due to the specificity of the siderocalin binding pocket, some 
functionalised enterobactin derivatives, and siderophores with structural differences 
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cannot be bound.9, 16, 17 Such stealth siderophores are therefore able to evade the 
host immunoprotein siderocalin, allowing for more effective iron acquisition.16-19 
Examples include the salmochelin siderophores, which are C5-glucosylated 
analogues of enterobactin, and its hydrolysis products, produced by pathogenic 
strains of Escherichia coli (Figure 2).20-23 They have high iron(III) affinity, but are 
more hydrophilic than enterobactin, with the glucose units providing steric bulk.24, 25 
These two properties allow the siderophores to avoid sequestration by siderocalin.26, 
27
 
V. cholerae can colonise the mammalian gut, where enterobactin and vibriobactin 
are sequestered by siderocalins.15-18, 28 Due to the high pathogenicity of Vibrio 
cholerae, estimated to cause at least 120,000 global deaths per year,29, 30 we were 
particularly interested to investigate whether this species is capable of employing 
salmochelin-type stealth siderophores. 
While a number of previous studies on the use of iron(III)-enterobactin in V. cholerae 
did not consider the potential presence of enterobactin hydrolysis products, such as 
tris(2, 3-dihydroxybenzoyl-L-serine) (trisDHBS), bis(2, 3-dihydroxybenzoyl-L-serine) 
(bisDHBS) and 2, 3-dihydroxybenzoyl-L-serine (DHBS), recent studies give a more 
complete picture of enterobactin-derived iron(III) acquisition.7, 31-34 Whilst it remains 
unclear whether or not intact cyclic enterobactin can support growth of V. cholerae, it 
is now accepted that iron(III)-trisDHBS and iron(III)-bisDHBS provide efficient iron(III) 
delivery pathways.34, 35 TonB, a protein that enables the active transport of essential 
nutrients, is required for the transport of iron(III)-siderophore complexes across the 
outer membrane via the two outer membrane receptor proteins VctA and IrgA for 
linear enterobactin derivatives,36 and the receptor for vibriobactin ViuA (Figure 3).31, 
37, 38
 Both periplasmic-binding protein dependent ABC transporters VctPDGC and 
ViuPDGC have been shown to transport iron(III)-vibriobactin and iron(III)-
enterobactin derivatives into the cytoplasm. Crystal structures have been reported 
for periplasmic binding proteins VctP and ViuP: VctP in the apo form (PDB ID: 
3TEF), and ViuP with vibriobactin bound (PDB ID:3R5T).39,4 
Our previous studies on the periplasmic binding protein CeuE from Campylobacter 
jejuni, which binds the tetradentate siderophore iron(III)-bisDHBS, revealed a strong 
similarity between CeuE and VctP.41, 42 VctP shares sequence similarities (25.3% 
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identical, 47.6% similar residues) and high structural similarities (r.m.s.d of 1.78 Å 
RYHU&ĮSRVLWLRQVPDWFKIRUVHFRQGDU\VWUXFWXUHHOHPHQWV3'%,'
3ZKW, 3TEF) with CeuE. Both proteins contain conserved histidine and tyrosine 
residues that complete coordination of the iron(III) centre of tetradentate siderophore 
complexes in CeuE.41-43 It is proposed that VctP has an analogous function to CeuE, 
and is optimised for binding tetradentate iron(III)-siderophore complexes. We here 
proceed to establish the siderophore-binding properties of VctP, to further 
understand its exact role in iron-uptake in V. cholerae. A number of catecholate 
siderophores and siderophore mimic compounds were screened for their binding 
affinity with VctP. A tetradentate salmochelin mimic was synthesised, its iron-binding 
properties characterised, and its interaction with CeuE and VctP evaluated. This 
study aimed to reveal whether these periplasmic binding proteins could be involved 
in uptake of Fe(III)-salmochelin S1 (Figure 2). This is the first indication that V. 
cholerae may employ salmochelin-type siderophores as an iron-uptake strategy that 
evades host siderocalin. 
1 Materials and Methods 
1.1 Siderophores and siderophore mimics 
Enterobactin was obtained from EMC microcollections (Tübingen) and used as 
supplied after compound purity was confirmed by HPLC and extinction coefficient 
determination. Bis(2, 3-dihydroxybenzoyl-L-serine) (bisDHBS) and bis(2, 3-
dihydroxybenzoyl)-1, 5-pentanediamine (5-LICAM) were synthesised as previously 
reported.42, 43 
1.2  Instrumentation 
NMR spectra were recorded on Jeol EX and ES 400 MHz instruments.  1H 
experiments were run at 399.78 MHz. 13C experiments were run at 100.53 MHz and 
were proton decoupled.  Positive and negative ion electrospray ionisation mass 
spectrometry (ESI-MS) was performed on a Bruker microTOF electrospray mass 
spectrometer. Elemental analysis was performed on an Exeter CE-440 elemental 
analyser. Infrared (ATIR) spectra were recorded on a Perkin Elmer FT-IR spectrum 
two spectrophotometer at ambient temperature. Melting points were determined 
using a Stuart Scientific SMP3 melting point apparatus. Specific rotation was 
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recorded on a Jasco DIP-370 digital polarimeter. Fluorescence spectra were 
recorded on a Hitachi F-4500 fluorescence spectrophotometer at ambient 
temperature. Electronic absorption spectra were recorded on a Shimadzu UV-1800 
spectrophotometer at ambient temperature. Circular dichroism was performed on a 
Jasco J810 CD spectropolarimeter at 20 °C under a constant flow of nitrogen.  
1.3 Synthesis of salmochelin mimics 
Methoxy-5-aceto-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate (5),44, 45 2, 3-
bis(benzyloxy)benzoic acid (9)46 and 2, 3-bis(benzyloxy)benzoic acid N-
hydroxysuccinimide ester (10)47 were prepared as documented in the literature. 
Compound structures with the atom numbering scheme used for the NMR 
assignments are available in the Supporting Information. 
1.3.1 Methyl-5-iodo-3-methoxysalicylate (2) 
Methyl-5-iodo-3-methoxysalicylate was prepared as in the literature, replacing the o-
vanillin substrate for 5.48 The crude product was recrystallised from a minimum 
amount of hot ethanol. (2.379 g, 7.72 mmol, 73%) Rf = 0.50 (1:4 ethyl acetate : 
petroleum ether 40-60°C) M.P = 109-111 °C. 1H NMR: (400 MHz, CDCl3į
(s, H9, 1H); 7.76 (d, J= 2.0 Hz, H4/6, 1H); 7.25 (d, J= 2.0 Hz, H4/6, 1H); 3.96 (s, 
H10, 3H); 3.89 (s, H8, 3H).13C NMR: (100 MHz, CDCl3į6 (C7); 152.0, 149.3, 
114.2 (C1, 2, 3); 129.5, 124.9 (C4,6); 56.4 (C8); 52.7 (C10). HRMS (ESI): Calcd. 
[M+H]+ (C9H9IO4) m/z = 308.9618; Obs. [M+H]+ m/z = 308.9629, Mean err 3.7 ppm. 
Calcd. [M+Na]+ (C9H9INaO4) m/z = 330.9438; Obs. [M+Na]+ m/z = 330.9446, Mean 
err 2.9 ppm. IR ATIR (cm-1): 3090 br w (C-H), 2943 w (C-H), 1674 m (C=O), 1607 m 
(C=C ar), 1471 s (C-H), 1343 m (O-H). 
1.3.2 Methyl-5-iodo-3-hydroxysalicylate (3) 
Methyl-5-iodo-3-hydroxysalicylate was prepared by adaptation of a literature 
protocol.49 Methyl-5-iodo-3-methoxysalicylate (2.000 g, 6.49 mmol) was dissolved in 
anhydrous dichloromethane (10 mL) and the mixture was stirred whilst the reaction 
flask was purged with N2. BBr3 (1 M in dichloromethane, 12 mL, 12.00 mmol) was 
added dropwise with vigorous stirring. The reaction flask was then purged again with 
N2 and the mixture stirred overnight at room temperature. The reaction mixture was 
opened to air, cold H2O (20 mL) was carefully added and the reaction mixture stirred 
for 1 hour. The resulting pale pink turbid mixture was dissolved in methanol (20 mL) 
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and the solvent removed in vacuo yielding a red residue. Methanol (10 mL × 3) was 
added to the residue, the residue dissolved, and the solvent removed in vacuo. The 
resulting peach coloured solid was redissolved in methanol (50 mL) and 
concentrated H2SO4 (2 mL) and heated under reflux overnight. The reaction mixture 
was cooled to room temperature and the solvent removed in vacuo, yielding a 
colourless oil and a white solid. The residue was dissolved in ethyl acetate (150 mL) 
and was washed with saturated NaHCO3 (3 x 90 mL) and brine (2 x 90 mL). The 
organic portion was dried over MgSO4, filtered and the solvent removed in vacuo 
yielding a white solid (1.710 g, 5.82 mmol, 89%) Rf = 0.47 (1:4 ethyl acetate : 
petroleum ether 40-60 °C) M.P = 136-138 °C (Lit. 133-134 °C).  HRMS (ESI): Calcd. 
[M+Na]+ (C9H9INaO4) m/z = 316.9281; Obs. [M+Na]+ m/z = 316.9282, Mean err 0.5 
ppm. Calcd. [M+2Na]+ (C9H9INa2O4) m/z = 338.9101; Obs. [M+2Na]+ m/z = 
338.9099, Mean err 0.2 ppm. 1H NMR, 13C NMR, HRMS (ESI): consistent with 
literature data.44 
1.3.3 Methyl-5-iodo-3, 4-benzyloxysalicylate (4) 
Methoxy-5-benzyloxy-5-iodo-3, 4-benzyloxysalicylate was prepared based on a 
literature protocol.44,45 The residue was dissolved in 1:1 chloroform : ethyl acetate 
(10 mL) and purified by flash column chromatography (1:9 ethyl acetate : petroleum 
ether 40-60°C) followed by recrystallisation in a minimu m amount of chloroform and 
an excess of petroleum ether 40-60°C. The white needle crystals were collected and 
dried in vacuo (1.613 g, 3.40 mmol, 78%) Rf = 0.37 (1:9 ethyl acetate : petroleum 
ether 40-60 °C) M.P = 103-105 °C (Lit. 105-106 °C). HRMS (ESI): [M+K]+ 
(C9H9INKO4) m/z = 512.9960; Obs. [M+K]+ m/z = 512.9957, Mean err 0.1 ppm. 1H 
NMR, 13C NMR, HRMS (ESI): consistent with literature data.44 
1.3.4 Methoxy-5-benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate (6) 
Methoxy-5-benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate was prepared based on 
a literature protocol.44, 45 Methoxy-5-aceto-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate 
(1.314 g, 1.94 mmol) was dissolved in dry methanol (100 mL) and Na2CO3 (1.026 g, 
9.68 mmol) was added. The resulting suspension was stirred under reflux at 65°C 
overnight, then reduced in vacuo to a pale brown solid. The solid was transferred to 
a Schlenk tube, and NaH (533 mg, 60% in mineral oil, 13.3 mmol) was added. The 
solids were dried in vacuo for two hours, before the addition of DMF (25 mL) and 
cooling of the solution to 0 °C. Bu 4NI was dried in vacuo for 15 minutes, to which, 
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benzyl bromide (3.00 mL, 4.320 g, 25.26 mmol) and DMF (5 mL) were added. The 
solution was cooled to 0 °C for 5 minutes, and was then added dropwise to the 
methyl-5-aceto-ȕ-(?-glucosyl-3,4-benzyloxysalicylate solution over 5 minutes at 0 °C. 
After 5 minutes of stirring at 0 °C, the pale brown r eaction mixture was stirred at RT 
under N2 overnight. The reaction mixture was opened to air, and deionised water (40 
mL) carefully added. The resulting solution was extracted with ethyl acetate (3 × 50 
mL). The organic portions were combined and dried over MgSO4, filtered and solvent 
removed in vacuo to yield a white solid. The solid was purified by column 
chromatography 20% ethyl acetate in petroleum ether 40-60°C yielding the product 
as a white solid (0.719 g, 0.82 mmol, 42%) Rf = 0.20 (20% ethyl acetate in petroleum 
ether 40-60°C) M.P = 84-86 °C.  HRMS (ESI): Calcd. [M+Na]+ (C56H54NaO9) m/z = 
893.3660; Obs. [M+Na]+ m/z = 893.3655, Mean err 0.6 ppm. 1H NMR, 13C NMR, 
HRMS (ESI): consistent with literature data.44 
1.3.5 Benzyloxy-5-benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate (7) 
Benzyloxy-5-benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate was prepared by the 
same method as methyl-5-benzyloxy-ȕ-(?-glucosyl-3,4-benzyloxysalicylate. The 
compounds were then separated by column chromatography yielding the product as 
a white solid. (0.381 g, 0.40 mmol, 21%) Rf = 0.26 (1:4 ethyl acetate : petroleum 
ether 40-60°C) M.P = 104-106 °C. 1H NMR: (400 MHz, CDCl3įGH6, J = 1.7 
Hz, 1H) 7.40-7.28 (m, H10, H15, H26-28, H31-33, H36-38, H41-43, H46-48, 29H); 
7.26-7.21 (m, H4, H11, H16, 5H) 6.94-6.92 (m, H12, H17, 2H) 5.34 (d, H44, J = 12.4 
Hz, 2H); 5.07 (d, H8, J = 10.1 Hz, 2H); 4.98 (d, H13, J = 2.2 Hz, 2H); 4.97-4.87 (m, 
H24/29, H39, 3H) 4.66-4.57 (m, H24/29/H23, 3H); 4.43 (d, H23, J = 10.1 Hz 1H); 
4.21 (d, H18, J = 9.5 Hz, 1H); 3.82-3.76 (m, H20/21/24/29, H34, 5H); 3.61-3.59 (m, 
H22, 1H); 3.44 (t, H19, J = 9.0 Hz, 1H). 13C NMR: (100 MHz, CDCl3į (C7); 
152.5 (C3); 148.0 (C2); 138.6 (C25); 138.2, 138.1, 137.4, 137.2, 136.3, 135.9, 
(C1/10/15/30/35/41/45); 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 128.2, 
128.1, 128.1, 128.0, 127.9, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 
127.6, 126.4 (C5/10-12/15-17/26-28/31-33/36-38/42-44/46-48); 122.0 (C6); 116.5 
(C4); 86.6 (C20/21); 83.9 (C19); 80.9 (C18); 79.3 (C22); 78.2 (C20/21); 75.6 (C8); 
75.1 (C24/29/34); 73.2 (C23); 70.9 (C39); 68.9 (C24/29/34); 68.1 (C13); 66.9 (C44). 
HRMS (ESI): Calcd. [M+Na]+ (C62H58NaO9) m/z = 969.3973; Obs. [M+Na]+ m/z = 
969.3982, Mean err 1.3 ppm.  
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1.3.6 1-Amino-5-(2,3-dibenzyloxybenzamide) pentane (11) 
1, 5-Diaminopentane (1.427 g, 14.00 mmol) and triethylamine (1.396 g, 13.80 mmol) 
were dissolved in THF (120 mL). A solution of 2, 3-bis(benzyloxy)benzoic acid N-
hydroxysuccinimide ester (3.008 g, 6.97 mmol) in THF (60 mL) was added dropwise 
over 2 hours and the mixture was left to stir overnight. The solvent was removed in 
vacuo yielding an off-white solid which was taken up in chloroform (120 mL) and 
washed with NaHCO3 (100 mL), brine (100 mL) and 2.25:1 1M HCl: brine (130 mL). 
The organic layer was dried over MgSO4, filtered and the solvent removed in vacuo. 
The residue was purified via silica column chromatography (90:10:1 CHCl3: MeOH: 
NH3(aq)). (1.859 g, 59 %) Rf = 0.18 (90:10:1 CHCl3: MeOH: NH3(aq)) M.P = 133-134 
°C. 1H NMR: (400 MHz, CDCl3įW- +] H8, 1H); 7.73-7.71 (m, H6/4, 
1H); 7.49-7.35 (m, H11-13, H16-18, 10H); 7.16 (d, J= 2.3 Hz, H6/4, 2H); 7.14 (t, J= 
4.6 Hz, H5, 1H); 5.16 (s, H9/14, 2H); 5.08 (s, H9/14, 2H); 3.27 (dd/q, J= 6.0 Hz J = 
13.3 Hz, H19,  2H); 2.77 (t, J= 6.6 Hz, H23, 2H); 1.48 (dt , J= 7.3 Hz, H20, 2H); 1.37-
1.20 (m, H21, H22, 4H). 13C NMR: (100 MHz, CDCl3į (C7); 151.7, 146.7, 
136.4, 128.7, 128.6, 128.6, 127.7 (C1-3/10-13/15-18); 124.4 (C4/6); 123.3 (C4/6); 
116.7 (C5);76.3, 71.2 (C9,14); 42.0 (C23); 39.6 (C19); 33.3, 29.1, (C20/22); 24.2 
(C21). HRMS (ESI): Calcd. [M+H]+ (C25H29N2O3) m/z = 405.2173; Obs. [M+H]+ m/z = 
405.2168, Mean err 3.5 ppm. IR ATIR (cm-1): 3365 m (N-H), 307b m br (N-H), 2803 
m br (C-H), 1641 m (C=O), 1571 m (C=C ar). 
1.3.7 Benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate (12) 
5-Benzyloxy-ȕ-(?-glucosyl-3,4-benzyloxysalicylate was prepared as in the literature.44, 
45
  Purification involved the addition of petroleum ether 40-60 °C (3 × 10 mL) and 
removal in vacuo to yield an off white solid residue. The residue was purified by 
column chromatography (1:4 methanol : chloroform) yielding a white solid product 
(0.359 g, 0.42 mmol, 87%) Rf = 0.56 (1:9 methanol : chloroform) M.P = 97-99 °C.  
HRMS (ESI): Calcd. [M+Na]+ (C55H52NaO9) m/z = 879.3504; Obs. [M+Na]+ m/z = 
879.3522, Mean err 2.4 ppm. 1H NMR, 13C NMR, HRMS (ESI): consistent with 
literature data.44 
1.3.8 5-Benzyloxy-ȕ-(?-glucosyl-bis(3, 4-benzyloxy)-5-LICAM (13) 
5-Benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxysalicylate (0.252 g, 0.29 mmol) was 
dissolved in DMF (10 mL) to which 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) (0.268 g, 0.70 mmol) 
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was added. The solution was stirred for one hour before the addition of N,N-
diisopropylethylamine (DIPEA) (184 µL, 0.137 g, 1.06 mmol) and 1-amino, 5-(2, 3-
dibenzyloxybenzamide) pentane (0.160 g, 0.35 mmol) and the mixture stirred 
overnight. The resulting brown solution was reduced in vacuo to a brown residue. 
The residue was purified twice by column chromatography (1:2 ethyl acetate : 
chloroform) (1:4 ethyl acetate : chloroform) yielding a white solid product (0.204 g, 
0.16 mmol, 55 %) Rf = 0.36 (1:4 ethyl acetate : chloroform) M.P = 96-98 °C . 1H NMR: 
(400 MHz, CDCl3įGH6, J = 1.8 Hz, 1H); 7.90 (m, H18/24,1H); 7.87 (t, 
H18/24, J = 5.5 Hz, 1H); 7.76 (dd, H29/31, J = 6.4 Hz, J = 3.2 Hz, 1H); 7.50-7.14 (m, 
H4/30/9-11/14-16/34-36/39-41/50-52/55-57/60-62/65-67, 42H); 6.98 (m, H29/31, 
2H); 5.17 (s, H12, 2H); 5.11-5.01 (m, H32/37, 2H); 5.08 (s, H32/37, 2H); 4.98 (br s, 
H7, 2H); 4.95-4.86 (m, H48/53, 3H); 4.67-4.56 (m, H53/64, 3H); 4.45 (d, H47, J = 
10.5 Hz, 1H); 4.26 (d, H42, J = 9.6 Hz, 1H); 3.86-3.73 (m, H47/44/58/46, 5H); 3.63 
(dt, H45, J = 9.2 Hz, J = 3.2 Hz, 1H); 3.52 (t, H43, J = 9.2 Hz, 1H); 3.25-3.18 (m, 
H19, H23, 4H); 1.30-1.23 (m, H20, H22, 4H); 1.16-1.10 (m, H21, 2H). 13C NMR: (100 
MHz, CDCl3į (C17/25); 164.7 (C17/25); 151.7 (C3/28); 151.4 (C3/28); 146.7 
(C2/27); 146.3 (C2/27); 138.7, 138.3, 137.7, 136.4, 136.3, 136.3, 136.3, 135.5 
(C8/13/33/38/49/54/59/64); 128.8, 128.7, 128.7, 128.6, 128.4, 128.4, 128.2, 128.2, 
128.2, 128.0, 127.8, 127.7, 127.6, 127.6, 127.5, 127.5, 127.4, 127.2 (C9-11/14-
16/34-36/39-41/50-52/55-57/60-62/65-67); 124.4 (C4/29/30/31); 123.3 
(C4/29/30/31); 122.2 (C4/29/30/31); 116.8(C29/31); 115.8 (C6); 86.7 (C44/46); 84.0 
(C43); 81.1 (C42); 79.3 (C45); 78.3 (C44/46); 76.4 (C32/37); 75.6 (C32/37); 75.1 
(C48/53); 74.9 (C47); 73.4 (C53/63); 71.2 (C32/37); 71.0 (C48/53); 69.1 (C58); 39.6 
(C19/23); 39.5 (C19/23); 28.9 (C20/22), 28.9 (C20/22), 24.5 (C21). HRMS (ESI): 
Calcd. [M+H]+ (C81H80N2Na1O11) m/z = 1279.5654; Obs. [M+Na]+ m/z = 1279.5606, 
Mean err 1.9 ppm. IR ATIR (cm-1): 3384 w br (N-H), 3287 w br (N-H), 3063 w (C-H), 
3030 w (C-H), 2920, 2859 w br (C-H), 1638 m (C=O), 1605 w (C=O), 1577 m (C=C 
ar). 
1.3.9 5-ȕ-(?-glucosyl-5-LICAM (14) 
5-ȕ-(?-Glucosyl-5-LICAM was prepared based on a literature protocol.44, 45 5-
Benzyloxy-ȕ-(?-glucosyl-3, 4-benzyloxy-4-LICAM (0.200 g, 0.1590 mmol) was 
dissolved in toluene (1 mL) and ethanol added (30 mL) followed by 3 spatula tips of 
Pd(OH)2 20% on carbon. The system was purged with nitrogen before purging with 
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hydrogen for 30 minutes. The reaction mixture was stirred under balloon pressure of 
hydrogen for 18 hours, and purged with nitrogen before opening to air. The catalyst 
was removed by filtration, and the solvent removed in vacuo to yield a pale 
colourless oil. The solid off white product was obtained by cooling the obtained oil in 
liquid nitrogen and removing all residual solvent in vacuo (0.086 g, 0.16 mmol, 90 
%). M.P = 180-182 °C.  1H NMR: 0+]0H2'įVH4/6, 1H); 7.20 (d, 
H20/22, J= 8.2 Hz 1H); 7.01 (s, H4/6, 1H); 6.91 (d, H20/22, J= 7.8 Hz, 1H); 6.70 (t, 
H21, J = 7.8 Hz, 1H); 4.02 (d, H26, J = 9.2 Hz, 1H); 3.87 (d, H34, J= 10.5 Hz, 1H); 
3.72 (dd, H34, 2JH34a/H34b = 11.9 Hz, 3JH34/H30 = 5.0 Hz, 1H); 3.46-3.35 (m, H11/15/27-
30, 8H); 1.72-1.64 (m, H12/14, 4H); 1.50-1.44 (m, H13, 2H). 13C NMR: (100 MHz, 
MeOD) į: 171.6 (C9/17); 171.6 (C9/17); 150.4 (C3/19); 150.3 (C3/19); 147.5 
(C2/18); 147.1 (C2/18); 131.3 (C1/23); 119.7 (C21/20/22); 119.4 (C21/20/22); 118.8 
(C4/6); 118.1 (C20/22); 116.9 (C4/6); 116.2 (C5); 83.3 (C26); 82.1 (C27/28/29/30); 
79.8 (C27/28/29/30); 76.5 (C27/28/29/30); 71.8 (C27/28/29/30); 63.0 (C34); 40.5 
(C11/15); 40.5 (C11/15); 30.3 (C12/14); 30.3 (C12/14), 25.6 (C13). HRMS (ESI): 
Calcd. [M+H]+ (C25H32N2O11) m/z = 535.1933; Obs. [M+H]+ m/z = 535.1912, Mean 
err 3.5 ppm. IR ATIR (cm-1): 3288 s br (O-H), 2930 m br (C-H), 1641 m (C=O), 1589 
m (C=C ar). Elemental Analysis: Calcd. for [C25H32N2O11.0.9EtOH.1.2H2O]: %C 
53.68, %H 6.70, %N 4.66; Measured for [C25H32N2O11.0.9EtOH.1.2H2O]: %C 53.76, 
%H 6.47, %N 4.52. Specific Rotation: >Į@D (Methanol, conc. 0.311 g/100 mL) + 5.7 
1.4 Jobs Plot 
The iron-binding properties of 5-ȕ-(?-glucosyl-n-LICAM (n = 4, 5) were investigated 
via a Job plot method.42 5-ȕ-(?-glucosyl-n-LICAM (n = 4, 5) was combined with 
varying concentrations of iron(III) to establish preferred metal to ligand binding ratios. 
The ratios spanned 100% ligand to 100% iron(III), with 5% intervals. Between 60:40 
and 50:50 ligand to iron(III) ratios, 2% intervals were used. This protocol resulted in 
24 samples over the full range. Stock solutions of 10 mM Fe(III)-nitrilotriacetate 
(NTA) in H2O and 10 mM 5-ȕ-(?-glucosyl-n-LICAM (n = 4, 5) in DMSO were used in 
the necessary ratios totalling 200 µL to make up a 2 mL solution of each ratio in 
1800 µL 0.11M Tris-HCl pH 7.5, 150 mM NaCl, resulting in an overall iron(III)-ligand 
concentration of 400 nM. DMSO was kept at 5% v/v for all final solutions. A UV/Vis 
spectrum from 400 nm to 700 nm was run for each solution after 1 hour of 
HTXLOLEUDWLRQ 7KHVSHFWUDZHUHUHUXQDIWHUGD\VRIHTXLOLEUDWLRQ Ȝmax values were 
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monitored at 495 nm and 555 nm and plotted against ligand to protein ratio, and the 
maximum absorbance for each wavelength recorded at the relevant ligand:protein 
ratio. 
1.5 Cloning, expression and purification  
CeuE was prepared as previously described.41, 43 The VctP gene for truncated VctP 
(residues 51-333), with signal peptide removed, was amplified by PCR from the 
synthetic DNA purchased from ThermoFisher scientific. Primers used were of the 
following sequence: FWD_51 
TCCAGGGACCAGCAGAGACAGTAACGATTGAACATCGCTTG, REV_333 
TGAGGAGAAGGCGCGTTACTGCATACCAACTGACGCTTTCATG. The gene 
product was directionally cloned into a Lic-adapted pET 28a vector (YSBLic3C), 
containing a 3C protease cleavable N-terminal hexa-histidine tag, by the In-Fusion 
method (Clontech). Protein was expressed in E .coli strain BL21(DE3). Cells were 
grown with shaking at 37q in Luria-Bertani broth media containing 30 Pg mL-1 
kanamycin and induced with 1 mM isopropyl E-d-thiogalactopyranoside at an OD600 
of 0.6-0.8. The cells were harvested by centrifugation 4 hours after induction and 
resuspended in buffer A (50 mM Tris-HCl, pH 7.8, 500 mM NaCl, 10 mM imidazole) 
in the presence of protease inhibitor cocktail and lysed by sonication on ice. The 
soluble crude extract was collected by centrifugation at 19,900 rpm. The standard 3-
step procedure was used for VctP purification. Initially a 5 mL His-Trap chelating 
column (Amersham Pharmacia) was charged with nickel and equilibrated with buffer 
A. Fractions containing VctP were eluted with buffer B (50 mM Tris-HCl, pH 7.8, 500 
mM NaCl, 500 mM imidazole). 3C protease for removal of the histidine tag was 
added in a 1:50 ratio to an overnight dialysis against buffer C (50 mM Tris-HCl, pH 
7.5, 150 mM NaCl). The cleaved sample was loaded in buffer C onto a second His-
Trap chelating column, and eluted with buffer B. Non-tagged protein was eluted in 
the flow-through (FT) fractions which were combined, concentrated by centrifugal 
ultrafiltration (Amicon Ultra) and purified by gel filtration on a Superdex S200 column 
in buffer D (50 mM Tris-HCl, pH 8.0; 150 mM NaCl). The final pure sample was 
concentrated to 90 mg mL-1. The molecular mass of the protein was confirmed by 
electro-spray mass spectrometry.  
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1.6 Fluorescence quenching titrations 
Intrinsic fluorescence quenching titrations were carried out as previously described.  
Spectra were recorded with an excitation of 280 nm, emission range of 295-410 nm, 
10 nm excitation slit width, 10 nm emission slit width, 60 nm/min scanning speed, 
automatic response, corrected spectra and 700 V detector voltage using a Hitachi F-
4500 fluorescence spectrophotometer.42, 43 
1.7 Circular Dichroism Spectroscopy 
Spectra were recorded in accordance with a published procedure,43 between 300 nm 
and 700 nm with data pitch 0.5 mm in continuous scanning mode with speed of 100 
nm min-1 and response of 2 seconds. The bandwidth was set to 2 nm, with a path 
length of 1 cm. Spectra were recorded five times and averaged. 
Solutions of CeuE and VctP were diluted to 2.5 × 10-3 M in 0.11 M Tris-HCl pH 7.5, 
150 mM NaCl buffer. A Fe(III)-ligand stock solution containing equimolar NTA was 
made at a concentration of 5 × 10-4 M, by adding 10 µL of both 10 mM ligand in 
DMSO and 10 µL 10mM Fe(III)-NTA in H2O to 180 µL 0.11 M Tris-HCl pH 7.5, 150 
mM NaCl buffer.  
Spectra were recorded of solutions containing 880 µL 0.11 M Tris-HCl pH 7.5, 150 
mM NaCl buffer, 100 µL (Fe(III)-ligand NTA stock solution and 20 µL 2.5 × 10-3 M 
CeuE, resulting in a 1:1 ratio of ligand to protein at 5 × 10-5 M. The spectrum of buffer 
was subtracted from all spectra including the spectra for free ligand and apo protein. 
 
2 Results and Discussion 
2.1 Salmochelin mimic synthesis 
A salmochelin mimic, Sal-5-LICAM (14), was designed based on a previously 
studied tetradentate siderophore mimic, 5-LICAM,43 and synthesised as shown in 
Scheme 1. The synthesis of aryl C-glycosides, such as (12), via metal-catalysed 
cross coupling reactions has previously been described.44, 45, 50, 51 
To obtain the iodinated intermediate (4) for the cross coupliing coupling step, 
commercially available (1) was selectively iodinated in the C5 position using iodine 
monochloride, silver nitrate and pyridine to yield (2),48 then demethylated via BBr3 
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deprotection (3), followed by benzyl ether protection of both phenolic hydroxyl 
groups to generate (4) in 51% yield7KHDFHWDWHSURWHFWHGȕ-(?-glucose unit was then 
installed at the C5 position via Negishi coupling of (4) with acetobromo-Į-(?-glucose, 
using a nickel catalyst and conditions adapted from a literature procedure.44 The 
activation of (4) using zinc, lithium and iodine in DMF reached completion within an 
hour and if the reaction mixture was left for 12 hours, as recommended in the 
literature,44 decomposition occured. By performing the subsequent Negishi coupling 
in a glovebox to avoid exposure to the atmosphere, a yield of 66% of (5) was 
obtained. 44, 45 The acetate protecting groups on the glucose unit were replaced with 
benzyl groups, yielding two products (6 and 7), which were combined and exposed 
to sodium hydroxide to afford (12) in 87% yield. Further details and reaction 
conditions are provided in the experimental section.    
In addition, compound 11 was synthesised, to allow for the selective generation of a 
mono-glucosylated salmochelin mimic. (8) was transformed into (9) via standard 
oxidation and benzyloxy protection reactions. 46 The carboxylic acid of (9) was 
activated via production of the N-hydroxysuccinimide ester (10), 47 which was then 
coupled with 1, 5-diaminopentane to produce amide bonded (11). The required 
second amide bond was formed between compounds (11) and (12) via a standard 
HATU coupling reaction yielding (13). Global deprotection of benzyl groups via 
standard hydrogenolysis afforded the target salmochelin-inspired siderophore mimic 
Sal-5-LICAM (14). 
2.2 Iron binding by Method of Continuous Variation 
Sal-5-LICAM (14) was complexed with iron(III) in varying ligand: iron(III) ratios, and 
the absorbance spectra recorded (Figure 4A). TKHȜmax was observed to shift from 
around 495 nm to around 555 nm as the Fe(III) to ligand ratio was increased. 
Plotting the absorbance at 555 nm and 495 nm for each spectrum over the range of 
ratios, gave the Job plot shown in Figure 4B. The  absorbance at 555 nm peaked at  
a 50:50 ratio, whilst the absorbance at 495 nm peaked at a 60:40 ratio. This 
indicated that a mixture of 1:1 species and a 3:2 species was present in solution, as 
represented by the schematic diagram in Figure 4D. After 7 days, the spectra were 
repeated, to establish whether further equilibration had been taken place. For both 
wavelengths, the maximum absorbance was achieved at a 60:40 ratio of Sal-5-
LICAM : Fe(III) (Figure 4C), which indicated that the 3:2 species is 
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thermodynamically more stable and predominates over time. Salmochelin 
siderophores are known to have a reduced membrane partition coefficient when 
compared to their enterobactin equivalents. 25 It may therefore be that the hydrophilic 
nature of the glucose moieties and their disposition to hydrogen bond in aqueous 
solution allows the ligands to assemble and form a 3:2 species with solvent exposed 
sugars shielding the hydrophobic backbones.53-54 However, considering the 
restricted iron levels within the host organism combined with the need for fast 
bacterial iron uptake, the kinetic 1:1 species is probably biologically more relevant. 
2.3 Binding of the salmochelin mimic to CeuE 
The interactions of the Fe(III) complex of the salmochelin mimic with CeuE were 
studied by circular dichroism (CD) spectroscopy (Figure 5A). In the absence of 
protein, no significant signal was observed in the wavelength range of the ligand-to-
metal charge transfer bandLQGLFDWLQJ WKDWDUDFHPLFPL[WXUHRIȁ- and ǻ-configured 
Fe(III) centres was present in solution. However, the CD spectrum obtained in the 
presence of  CeuE shows clear negative bands between 310 and 540 nm and a 
weak positive band above 550 nm. These bands are indicative of Fe(III)-
catecholamide complexes that adopt the ȁ-configuration. A similar chiral preference 
was previously reported for similar bis(catecholate) siderophores and mimics41-43 and 
shown by X-ray crystallography to originate from H-bonding and electrostatic 
interactions with the chiral binding pocket of CeuE and the direct coordination of two 
amino acid side chains, Tyr288 and His227, to the Fe(III) centre. Hence, the CD 
spectra confirmed  that CeuE is able to bind the Fe(III) complex of the salmochelin 
S1 mimic and that CeuE VKRZVDSUHIHUHQFHIRUȁ-configured coordination centres. 
A subsequent fluorescence quenching titration of CeuE with Fe(III)-Sal-5-LICAM 
(Figure 5B), gave a dissociation constant of 511 ± 76 nM, around 50 times larger 
than that for the binding of Fe(III)-5-LICAM or the natural siderophore Fe(III)-
bisDHBS with CeuE.42, 43 This suggests that although CeuE is able to bind Fe(III)-
Sal-5-LICAM, it appears better suited to the binding of Fe(III)-bisDHBS than 
salmochelin S1. 
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2.4 Binding of the salmochelin-inspired iron(III)-siderophore 
mimic to VctP 
The CD spectra obtained upon addition of Fe(III)-Sal-5-LICAM to VctP also showed 
DQLQGXFHGȁ-configuration (Figure 6A). As VctP contains conserved histidine and 
W\URVLQHUHVLGXHVLWLVOLNHO\WKDWWKHȁ-configured binding mode between Fe(III)-
bound tetradentate siderophores is similar in VctP and CeuE. VctP was titrated with 
Fe(III)-Sal-5-LICAM in triplicate giving a dissociation constant of 9.4 ± 3.0 nM (Figure 
6B). Thus VctP binds salmochelin S1 with high affinity, which suggests that V. 
cholerae is able to use the salmochelin stealth siderophores for Fe(III)-uptake via the 
VctPDGC system.  
 
2.5 Comparison of the iron(III)-siderophore binding properties of 
VctP with those of CeuE 
Dissociation constants were measured for VctP titrated with Fe(III)-enterobactin, 
Fe(III)-bisDHBS, Fe(III)-5-LICAM and compared with those obtained for CeuE ( 
Table 1). VctP bound Fe(III)-enterobactin with a dissociation constant of 369 ± 25 
nM, and with ȁ-configured complexes dominating in solution. This affinity was 
around ten times stronger than that estimated for the binding of CeuE to Fe(III)-
enterobactin. The binding of VctP to both Fe(III)-bisDHBS and Fe(III)-5-LICAM was 
too strong to be quantified via fluorescence quenching titrations, due to reaching the 
limits of detection, and were both estimated to be in the sub-nanomolar range. These 
results suggest that VctP is able to bind tetradentate catecholate siderophores with 
very high affinity, including the salmochelin S1 mimic Sal-5-LICAM, but may also be 
able to use enterobactin for iron uptake in V. cholerae. The ability to use both 
tetradentate and hexadentate catecholate siderophores, as well as stealth 
siderophores, may contribute to the virulence of V. cholerae. 
3 Summary and conclusions 
The salmochelin S1 mimic Sal-5-LICAM was synthesised, characterised and shown 
to form both 1:1 and 3:2 complexes if equilibrated for one hour ([L] + [M] = 0.4 mM). 
Similar iron(III)-binding stoichiometries of 1:1 and 3:2 were observed previously with 
other bis(catecholates), such as 4-LICAM and bisDHBS.41, 42  Only after a further 
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equilibration period of seven days was the thermodynamically more stable 3:2 
complex seen to predominate. Initial protein-binding studies with diastereoisomeric 
mixtures of the Fe(III) complexes were carried out by CD spectroscopy and showed 
that both periplasmic binding proteins, CeuE of C. jejuni and VctP of V. cholerae, 
preferentially select for ȁ-configured Fe(III) complexes of the salmochelin S1 mimic, 
as seen previously upon binding of bis(catecholates) to CeuE.41-43 
Subsequent intrinsic fluorescence quenching titrations revealed that VctP binds the 
Fe(III) complexes of all catecholate siderophores tested (enterobactin, bisDHBS, 5-
LICAM and Sal-5-LICAM) with higher affinity than does CeuE. In addition, both CeuE 
and VctP display a clear preference for tetradentate bis(catecholates), such as 
bisDHBS, 5-LICAM and Sal-5-LICAM, over the tris(catecholate) enterobactin. In 
case of CeuE, the structural basis for this preference for tetradentate siderophores 
originates from two protein side chains (Tyr288 and His227) that coordinate directly 
to the Fe(III) centre,41-43 whilst the coordination of these side chains to Fe(III) 
enterobactin is not possible, due to a lack of available coordination sites. The 
observed preference of tetradentate siderophores is also consistent with the report 
that V. cholerae utilises the enterobactin hydrolysis product bisDHBS for the 
acquisition of Fe(III), but not intact enterobactin.34 and the finding that bisDHBS is a 
functional Fe(III) uptake mediator in C. jejuni.55 
Our results suggest that the role of the tetradentate stealth siderophore salmochelin 
S1 in the iron uptake of enteric pathogens merits further investigation as it may be of 
importance in iron cross-feeding within environments that are shared with 
salmochelin-producing E. coli strains, for example inflamed mammalian small 
intestines.56 Salmochelin S1 utilisation may provide scavenging pathogenic species 
with a competitive advantage in microbiota where the Fe(III) complexes of 
enterobactin and vibriobactin are being removed by the innate defence protein 
siderocalin, whilst glucosylated stealth siderophore, such as salmochelin S1, evade 
capture.15-18, 28  
 
18 
4 Acknowledgements 
Funding: We would like to thank the EPSRC (grant no. EP/L024829/1, and 
studentship for E.J.W.) for support. 
Competing interests: The authors declare no competing interests. 
 
References 
1. C. Ratledge and L. G. Dover, Annu. Rev. Microbiol. 54 (2000) 881-941. 
2. M. L. Guerinot, Annu. Rev. Microbiol. 48 (1994) 743-772. 
3. C. Wandersman and P. Delepelaire, Annu. Rev. Microbiol. 58 (2004) 611-647. 
4. R. C. Hider and X. Kong, Nat. Prod. Rep. 27 (2010) 637-657. 
5. J. R. Butterton and S. B. Calderwood, J. Bacteriol. 176 (1994) 5631-5638. 
6. E. E. Wyckoff, A.-M. Valle, S. L. Smith and S. M. Payne, J. Bacteriol. 181 
(1999) 7588-7596. 
7. E. E. Wyckoff, A. R. Mey and S. M. Payne, Biometals 20 (2007) 405-416. 
8. B. E. Allred, T. Hoette and K. N. Raymond, Abstr. Pap. Am. Chem. Soc., 239 
(2010) 1. 
9. T. M. Hoette, R. J. Abergel, J. D. Xu, R. K. Strong and K. N. Raymond, J. Am. 
Chem. Soc. 130 (2008) 17584-17592. 
10. R. J. Abergel, M. C. Clifton, J. C. Pizarro, J. A. Warner, D. K. Shuh, R. K. 
Strong and K. N. Raymond, J. Am. Chem. Soc. 130 (2008) 11524-11534. 
11. M. A. Holmes, W. Paulsene, X. Jide, C. Ratledge and R. K. Strong, Structure 
13 (2005) 29-41. 
12. B. E. Allred, P. B. Rupert, S. S. Gauny, D. D. An, C. Y. Ralston, M. 
Sturzbecher-Hoehne, R. K. Strong and R. J. Abergel, Proc. Natl. Acad. Sci. 112 
(2015) 10342-10347. 
13. B. E. Allred, C. Correnti, M. C. Clifton, R. K. Strong and K. N. Raymond, ACS 
Chem. Biol. 8 (2013) 1882-1887. 
19 
14. G. Bao, M. Clifton, T. M. Hoette, K. Mori, S.-X. Deng, A. Qiu, M. Viltard, D. 
Williams, N. Paragas, T. Leete, R. Kulkarni, X. Li, B. Lee, A. Kalandadze, A. J. 
Ratner, J. C. Pizarro, K. M. Schmidt-Ott, D. W. Landry, K. N. Raymond, R. K. Strong 
and J. Barasch, Nat. Chem. Biol., 6 (2010) 602-609. 
15. D. H. Goetz, M. A. Holmes, N. Borregaard, M. E. Bluhm, K. N. Raymond and 
R. K. Strong, Mol. Cell 10 (2002) 1033-1043. 
16. E. P. Skaar, Cell Host Microbe 5 (2009) 422-424. 
17. A. K. Sia, B. E. Allred and K. N. Raymond, Curr. Opin. Chem. Biol. 17 (2013) 
150-157. 
18. E. P. Skaar, PLOS Pathogens 6 (2010) e1000949. 
19. M. Caza, A. Garenaux, F. Lepine and C. M. Dozois, Molec. Microbiol. 97 
(2015) 717-732. 
20. M. Valdebenito, B. Bister, R. Reissbrodt, K. Hantke and G. Winkelmann, Int. 
J. Med. Microbiol. 295 (2005) 99-107. 
21. M. Valdebenito, A. L. Crumbliss, G. Winkelmann and K. Hantke, Int. J. Med. 
Microbiol. 296 (2006) 513-520. 
22. M. G. Zhu, M. Valdebenito, G. Winkelmann and K. Hantke, Microbiology 151 
(2005) 2363-2372. 
23. S. I. Elshahawi, K. A. Shaaban, M. K. Kharel and J. S. Thorson, Chem. Soc. 
Rev. 44 (2015) 7591-7697. 
24. B. Bister, D. Bischoff, G. Nicholson, M. Valdebenito, K. Schneider, G. 
Winkelmann, K. Hantke and R. Süssmuth, Biometals 17 (2004) 471-481. 
25. M. Luo, H. Lin, M. A. Fischbach, D. R. Liu, C. T. Walsh and J. T. Groves, ACS 
Chem. Biol. 1 (2006) 29-32. 
26. K. Hantke, G. Nicholson, W. Rabsch and G. Winkelmann, Proc. Natl. Acad. 
Sci. 100 (2003) 3677-3682. 
27. S. Muller, M. Valdebenito and K. Hantke, Biometals 22 (2009) 691-695. 
20 
28. A. L. Nelson, J. M. Barasch, R. M. Bunte and J. N. Weiser, Cell. Microbiol. 7 
(2005) 1404-1417. 
29. S. M. Faruque, M. J. Albert and J. J. Mekalanos, Microbiol. Mol. Biol. Rev. 62 
(1998) 1301-1314. 
30. D. A. Sack and S. R Bradley Sack MD, N. Engl. J. Med. 355 (2006) 649-651. 
31. A. R. Mey, E. E. Wyckoff, A. G. Oglesby, E. Rab, R. K. Taylor and S. M. 
Payne, Infect. Immun. 70 (2002) 3419-3426. 
32. E. E. Wyckoff, A. R. Mey, A. Leimbach, C. F. Fisher and S. M. Payne, J. 
Bacteriol. 188 (2006) 6515-6523. 
33. E. E. Wyckoff and S. M. Payne, Molec. Microbiol. 81 (2011) 1446-1458. 
34. E. E. Wyckoff, B. E. Allred, K. N. Raymond and S. M. Payne, J. Bacteriol. 197 
(2015) 2840-2849. 
35. J. Rutz, T. Abdullah, S. Singh, V. Kalve and P. Klebba, J. Bacteriol. 173 
(1991) 5964-5974. 
36. S. S. Seliger, A. R. Mey, A. M. Valle and S. M. Payne, Molec. Microbiol. 39 
(2001) 801-812. 
37. S. M. Payne, A. R. Mey and E. E. Wyckoff, Microbiol. Mol. Biol. Rev. 80 
(2016) 69-90. 
38. J. R. Butterton, J. A. Stoebner, S. M. Payne and S. B. Calderwood, J. 
Bacteriol. 174 (1992) 3729-3738. 
39. N. Li, C. Zhang, B. Li, X. Liu, Y. Huang, S. Xu and L. Gu, J. Biol. Chem. 287 
(2012) 8912-8919. 
40. X. Liu, Q. Du, Z. Wang, S. Liu, N. Li, Y. Chen, C. Zhu, D. Zhu, T. Wei and Y. 
Huang, FEBS Lett. 586 (2012) 1240-1244. 
41. D. J. Raines, O. V. Moroz, K. S. Wilson and A. K. DuhmeǦKlair, Angew. 
Chem., Int. Ed. Engl. 52 (2013) 4595-4598. 
42. D. J. Raines, O. V. Moroz, E. V. Blagova, J. P. Turkenburg, K. S. Wilson and 
A.-K. Duhme-Klair, Proc. Natl. Acad. Sci. 113 (2016) 5850±5855. 
21 
43. E. J. Wilde, A. Hughes, E. V. Blagova, O. V. Moroz, R. P. Thomas, J. P. 
Turkenburg, D. J. Raines, A.-K. Duhme-Klair and K. S. Wilson, Sci. Rep. 7 (2017) 
45941-45955. 
44. H. G. Gong and M. R. Gagne, J. Am. Chem. Soc. 130 (2008) 12177-12183. 
45. X. Yu, Y. Dai, T. Yang, M. R. Gagné and H. Gong, Tetrahedron 67 (2011) 
144-151. 
46. W. H. Rastetter, T. J. Erickson and M. C. Venuti, J. Org. Chem. 46 (1981) 
3579-3590. 
47. A. Chimiak and J. B. Neilands, in Siderophores from Microorganisms and 
Plants, Springer Berlin Heidelberg, Berlin, Heidelberg, 1984, pp. 89-96. 
48. A. V. Joshua, S. K. Sharma and D. N. Abrams, Synth. Commun. 38 (2008) 
434-440. 
49. A.-K. Duhme, Z. Dauter, R. C. Hider and S. Pohl, Inorg. Chem. 35 (1996) 
3059-3061. 
50. )=KX-5RGULJXH]7<DQJ,.HYOLVKYLOL (0LOOHU'<L62¶1HLOO 
M. J. Rourke, P. Liu, and M. A. Walczak, J. Am. Chem. Soc. 139 (2017) 17908-
17922. 
51.  L. Adak, S. Kawamura, G. Toma, T. Takenaka, K. Isozaki, H. Takaya, A. 
Orita, H. C. Li, T. K. M. Shing and M. Nakamura, J. Am. Chem. Soc. 139 (2017) 
10693-10701. 
52. F. M. Raymo and J. F. Stoddart, Chem. Ber. 129 (1996) 981-990. 
53. M. L. Saha, S. De, S. Pramanik and M. Schmittel, Chem. Soc. Rev. 42 (2013) 
6860-6909. 
54. M. Albrecht, Chem. Rev. 101 (2001) 3457-3498. 
55. C. Y. Zamora, A. G. E. Madec, W. Neumann, E. M. Nolan, B. Imperiali, 
Bioorg. Med. Chem., 2018, in press, https://doi.org/10.1016/j.bmc.2018.04.030. 
56.  G. A. M. Kortman, M. Raffatellu, D. W. Swinkels and H. Tjalsma, FEMS 
Microbiol. Rev. 38 (2014) 1202-1234. 
22 
 
 
Table 1: Dissociation constants for CeuE and VctP with a selection of Fe(III)-
siderophores and Fe(III)-siderophore mimics, as determined by fluorescence 
quenching titrations. 
Fe(III)-Ligand CeuE Kd /nM VctP Kd /nM 
Enterobactin 3500 ± 300 369 ± 25 
bisDHBS 10.1 ± 3.8 (lit.42) <1 
5-LICAM <10 (lit.43) <1 
Sal-5-LICAM 511 ± 76 9.4 ± 3.0 
40 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, titrations were 
performed as independent triplicates, with the uncertainty in 
the average shown. 
 
 
Figure and scheme captions: 
Figure 1: Catecholate siderophores used by Vibrio cholerae for iron(III)-uptake.7 
Figure 2: Salmochelin siderophores.24 
Figure 3: Known functions of proteins involved in Fe(III) catecholate siderophore 
uptake in V. cholerae. Uptake through the outer membrane is mediated by the outer 
membrane receptors VctA, IrgA and ViuA, which are energised by the TonB-ExbB-
ExbD complex. Periplasmic binding proteins (VctP, ViuP) capture the Fe(III) 
siderophore complexes in the periplasm for subsequent uptake through the inner 
membrane transporters VctDG, VctC, ViuDG and ViuC. In the cytoplasm, ViuB 
facilitates the release of the iron form its siderophore complex via reduction of Fe(III) 
23 
to Fe(II).  Ent = enterobactin, Vib = vibriobactin, trisDHBS = tris(2, 3-
dihydroxybenzoyl-L-serine), bisDHBS = bis(2, 3-dihydroxybenzoyl-L-serine). 
Figure 4: Selected electronic absorbance spectra obtained at the indicated metal-to-
ligand ratios; [M]+[L] = 0.4 mM; 0.1 M Tris-HCl; 150 mM NaCl; 5% v/v DMSO; pH 7.5 
(A), Job plots (B: 1 hour C: 7 days) for the reaction of Sal-5-LICAM with iron(III), and 
schematic representation of a 1:1 and 3:2 tetradentate ligand : iron complex (D) 
(solvent molecules are depicted as Sol). 
Figure 5: A: CD spectra for Fe(III)-Sal-5-/,&$0VKRZLQJVRPHLQGXFHG ȁ-
configuration upon complexation with CeuE. B:  Fluorescence quenching titration 
curves (in triplicate) obtained with CeuE and Fe(III)-Sal-5-LICAM. 
Figure 6: A: CD spectra for Fe(III)-Sal-5-/,&$0VKRZLQJȁ-configuration upon 
binding to VctP. B: Triplicate binding curves for fluorescence quenching titration of 
VctP with Fe(III)-Sal-5-LICAM. 
Scheme 1: Synthesis of Sal-5-LICAM (14) a: AgNO3, ICl, Pyridine, CHCl3 b: 1) BBr3, 
DCM 2) H2SO4, MeOH, 75 ºC c: BnBr, NaI, DMF d: 1-Bromo-Į-D-glucose 
tetraacetate, Zn, LiCl, Ni(COD)2, tBuTerpy, DMF e: 1) Na2CO3, MeOH 2) BnBr, NaH, 
Bu4NI, DMF f: NaOH, THF, MeOH g: 1) BnCl, K2CO3, EtOH 2) H3NSO3, NaClO3, 
Acetone, H2O h: N-hydroxysuccinimide, DCC, Dioxane i:1,5-diaminopentane, Et3N, 
THF j: HATU, Et3N, DMF k: H2, Pd(OH)2/C 10%, EtOH/Toluene. 
Figures and schemes: 
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